Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b01dcd61775e996fac631d4b10c4e87f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69b5b385097fedde4c187afb1359b1e9 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
filingDate |
2017-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_967025635c7ca587546fad2d49ab7dbc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbd7aef8540fda49553a725f154bf528 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ddcec996131aa3c0a186f4d6128e56d |
publicationDate |
2018-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2018039824-A |
titleOfInvention |
Methods and compositions for the treatment of fluid retention in and / or under the retina |
abstract |
The present invention provides methods and compositions for the treatment of fluid retention in and / or under the retina. A pharmaceutical composition comprising a mineralocorticoid receptor gene expression inhibitor for use in the treatment of fluid retention in and / or under the retina associated with central serous chorioretinopathy. A pharmaceutical composition further comprising a glucocorticoid, wherein the mineralocorticoid receptor gene expression inhibitor is an antisense oligonucleotide or siRNA. [Selection figure] None |
priorityDate |
2010-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |